Company intelligence / Profile preview

Anulex Technologies

Minnetonka, Minnesota, United Statestcomn.com ↗

Ownership: Private
Employees: ~21
Development stage: Other

Overview

Anulex Technologies developed and commercialized proprietary medical devices for soft tissue repair in spinal surgery. Its flagship product, the Xclose Tissue Repair System, received FDA 510(k) clearance in 2006 for use in soft tissue approximation. The company conducted a large prospective randomized study on annular repair with its device but ultimately faced regulatory challenges and market competition that led to its closure around or before 2018.

Therapeutic areas: Neurology
Modalities: DeviceSurgical implantable devices
Industry: Surgical Medical Devices

Partnerships

None reported.

Beyond the preview

Go deeper on Anulex Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anulex Technologies.

Explore the full profile